TABLE 1.
Participant characteristics
| Cancer patients (n = 68) | Healthy donors (n = 231) | |
|---|---|---|
| Mean age, years (range) | 52·6 (28–79) | 41·4 (18–81) |
| Sex | ||
| Male | 25/68 (36·8%) | 81/231 (35·1%) |
| Female | 43/68 (63·3%) | 150/231 (64·9%) |
| Vaccine status | ||
| Pfizer (BNT162b2) | 68/68 (100·0%) | 95/231 (41·1%) |
| AstraZeneca (ChAdOx1 nCoV−19) | 0/68 (0%) | 76/231 (32·9%) |
| Unknown vaccine | 0/68 (0%) | 2/231 (0·9%) |
| Unvaccinated a | 0/68 (0%) | 58/231 (25·1%) |
| Malignancy | ||
| Breast | 20/68 (29·4%) | N/A |
| Gastrointestinal | 16/68 (23·5%) | N/A |
| Prostate | 8/68 (11·8%) | N/A |
| Lung | 5/68 (7·4%) | N/A |
| Female reproductive | 5/68 (7·4%) | N/A |
| Melanoma | 3/68 (4·4%) | N/A |
| Brain | 3/68 (4·4%) | N/A |
| Other | 8/68 (11·8%) | N/A |
| Cancer treatment on study | ||
| Chemotherapy | 22/68 (32·4%) | N/A |
| Immunotherapy | 7/68 (10·3%) | N/A |
| Radiotherapy | 3/68 (4·4%) | N/A |
| Hormone treatment | 14/68 (20·6%) | N/A |
| Tyrosine kinase inhibitors | 11/68 (16·2%) | N/A |
| Not on treatment | 11/68 (16·2%) | N/A |
a
Indicates participants where only a pre‐vaccination blood sample was obtained.